Image source: The Motley Fool.

DATE

Monday, May 18, 2026 at 8 a.m. ET

CALL PARTICIPANTS

• Chief Executive Officer — Jonathan Javitt
• Chief Financial Officer — Michael Abrams

Need a quote from a Motley Fool analyst? Email [email protected]

TAKEAWAYS

• Debt Position -- NRx Pharmaceuticals (NRXP 0.70%) reduced its debt from $8.7 million to zero, becoming debt-free as of the end of the reported quarter.
• Cash and Liquidity -- The company reported $6.7 million in cash and cash equivalents as of March 31, 2026, and subsequently raised $7 million from stock sales, with management stating "sufficient cash for our immediate operating needs."
• Net Loss -- Net loss was $1.4 million or $0.04 per share, a 74% decrease from $5.5 million or $0.34 per share in the comparable 2025 period.
• Operating Loss -- Loss from operations increased to $4.7 million from $3.8 million in the prior year quarter, primarily due to expenses related to targeted strategic initiatives and pipeline expansion.
• Research and Development Expense -- R&D expense rose to $1.3 million from $0.8 million year over year.
• General and Administrative Expense -- G&A expense, including selling costs, increased to $3.8 million from $2.9 million year over year.
• KETAFREE Regulatory Progress -- Jonathan Javitt issued "a labeling letter requesting only minor formatting changes and a positive disciplined review letter on quality, requesting only administrative changes that FDA itself identified is minor," with commercial manufacturing initiated at a scale of 1 million units per batch.
• FDA Manufacturing Status -- The manufacturing site was reclassified by the FDA to VAI status, consistent with the launch of an ANDA drug.
• Supply Capacity -- Management stated capability to manufacture 1 million units per week using blow-fill seal technology, with at least 1 million units to be warehoused at launch.
• Ketamine Drug Shortage -- KETAFREE targets a market experiencing ongoing ketamine shortages, as sterile intravenous ketamine "remains on the ASHP National Drug Shortage database."
• NRX-100 Regulatory Pathway -- The company plans NDA submission in the second quarter, supported by clinical trial data from over 1,000 patients and real-world evidence from more than 65,000 patients, following FDA guidance to seek an indication of depression with suicidality.
• Government Policy Tailwinds -- Management highlighted a presidential executive order and Congressional appropriations language directing the use of real-world evidence in the FDA approval process for psychedelic medicines treating depression, PTSD, and suicidality.
• NRX-101 Trial -- FDA granted clearance to begin the MIND1 Phase IIb/III trial of NRX-101 plus TMS, targeting 400 participants, with nondilutive federal funding anticipated.
• HOPE Therapeutics Expansion -- HOPE operated 5 clinics in the quarter and expects to reach at least 8 locations by the end of the following quarter, implementing EMOBOT Health’s AI-driven depression monitoring technology across its network.
• Geneuro Acquisition -- The company acquired assets from Geneuro, SA via a court-supervised liquidation, adding a portfolio focused on human endogenous retroviruses (HERVs), cell lines, patent rights, and data from pre-completed human clinical trials, funded with existing cash.

SUMMARY

NRx Pharmaceuticals made significant operational progress by clearing key U.S. regulatory milestones for KETAFREE, advancing manufacturing plans, and initiating commercial leadership appointments to prepare for market entry. The company’s NRX-100 NDA will be uniquely supported by both clinical and real-world data, with FDA guidance suggesting the potential for a broad depression indication and recent U.S. policy changes potentially accelerating review. The FDA’s approval of the MIND1 trial enables immediate forward movement on NRX-101/TMS development targeting major psychiatric indications, while HOPE Therapeutics expanded technological integration and clinical footprint. Strategic acquisition of Geneuro assets broadened the R&D pipeline into neuroinflammatory diseases, leveraging preclinical and clinical-stage assets to potentially access new non-dilutive funding channels.

• “Leadership of the FDA Office of Generic Drugs expressed support for addressing the remaining items within the current review cycle, consistent with our summer 2026 goal.”
• Management expects nondilutive federal funding to support military and academic trial sites in the MIND1 study.
• Jonathan Javitt stated that "Availability of raw material is not a problem," mitigating supply chain risks for launch-scale manufacturing.
• The existing commercial ketamine market is estimated by management to exceed $750 million, with the reference product SPRAVATO generating about $2 billion annually.
• Management described its current cash position, anticipated clinic revenue growth, cost controls, and at-the-market facility as supporting operations “through at least 2026.”

INDUSTRY GLOSSARY

• ANDA: Abbreviated New Drug Application, the regulatory pathway for U.S. generic drug approval by the FDA.
• BFS (Blow-fill seal): A technology for aseptic drug manufacturing that eliminates glass vials and stoppers, enabling high-volume, lower-cost production.
• D-cycloserine: An NMDA receptor modulator investigated as an augmenting agent to transcranial magnetic stimulation in depression clinical trials.
• EMOBOT: AI-driven digital tool for passive depression monitoring, leveraging facial cues and actigraphy, deployed in clinical networks.
• HERV (Human Endogenous Retrovirus): Virus-derived sequences in the human genome; implicated in autoimmune and neuropsychiatric disorders.
• VAI status: Voluntary Action Indicated; a favorable FDA facility classification, permitting launch-related activity with only minor issues identified.

Full Conference Call Transcript

Jonathan Javitt: Thank you, Brian. Good morning, everyone. Thank you for joining us. The first quarter of 2026 was a productive one for NRx. We made progress on both regulatory pathways for preservative-free ketamine, initiated commercial manufacturing, advanced NRX-101 into a registrational trial, continued to grow the HOPE Therapeutics network and acquired the Geneuro assets. A year ago, we had not yet filed for our first drug approval and we were $8.7 million in debt. Now we are debt-free. We have sufficient cash for our immediate operating needs, and we've raised $7 million since the end of the quarter. We've reduced our financial statement loss by 74% year-over-year. Let me start with KETAFREE.

As we reported in March, FDA notified us of a preliminary determination of bioequivalents to the reference branded drug, Ketalar. Since then, we've continued to clear the remaining review disciplines. In April, FDA issued a labeling letter requesting only minor formatting changes and a positive disciplined review letter on quality, requesting only administrative changes that FDA itself identified is minor. Leadership of the FDA Office of Generic Drugs expressed support for addressing the remaining items within the current review cycle, consistent with our summer 2026 goal. We are at the verge of entering a robust market where ketamine is in drug shortage at the exact moment when reliability matters most, and we're positioned to deliver it.

From our perspective, the market shortage of ketamine is larger than is apparent from hospital data because the rapidly growing ketamine clinic market segment is frequently unable to obtain ketamine through the commercial supply chain and must rely on compounding pharmacies. FDA has now reclassified our manufacturing site to VAI status, consistent with the launch of an ANDA drug. And on May 5, we transmitted our first commercial manufacturing order at the 1 million unit per batch scale. The blow-fill seal process we're using delivers more than tenfold throughput compared to traditional glass bi techniques and is readily scalable at substantially lower manufacturing cost. Simply put, the most expensive component in traditional manufactured ketamine is the glass vial.

With blow-fill seal or BFS, there is no glass vial, no rubber stopper and we calculate that we are capable of manufacturing 1 million units per week. Timing matters here. As of April, sterile intravenous ketamine remains on the ASHP National Drug Shortage database. KETAFREE will be the first U.S. manufactured preservative-free ketamine, free of benzethonium chloride a preservative that is not generally recognized as safe and is no longer permitted even in hand cleansers and topical antiseptics. To prepare for launch, in April, we appointed Glenn Tyson as our first Chief Commercial Officer. Glenn brings 25 years of commercial leadership in GSK and Indivior, where he led the successful launch of SUBLOCADE.

Glenn is in the process of bringing on his launch team of accomplished pharmaceutical executives, and we look forward to introducing them to you in the near future. As we prepare for anticipated approval of our preservative-free ketamine, we're entering a market that is already well established but structurally undersupplied. Sterile ketamine has remained on national drug shortage listings, as we mentioned, with intermittent back orders, product discontinuations and inconsistent availability across hospital and outpatient settings. At the same time, clinical demand continues to expand across both anesthesia and psychiatric use, supported by widespread off-label adoption and established infusion infrastructure.

It's important to recognize that ketamine is rapidly becoming a substitute for opioids in many pain control protocols and federal law is increasingly discouraging the use of opioids as a state law. We believe this creates a highly attractive initial commercial opportunity where reliability of supply and quality of manufacturing are as important as price. With U.S.-based production, scalable manufacturing capability and a preservative-free profile, our goal is to provide a consistent and trusted source of ketamine at a time when clinicians are actively seeking alternatives to constrain supply on one hand and alternatives to using opioids on the other. We believe our product represents the first domestically manufactured source of preservative-free ketamine.

And we further reinforced this position through our previously filed citizen petition supporting standards for preservative-free formulations. Turning to NRX-100. As we shared in March, our Type C meeting with the leadership of the FDA Division of Psychiatry Products and the Center for Drug Evaluation and Research confirmed FDA's willingness to review existing clinical trial data together with real-world evidence as potential basis for approval without a requirement for additional trials. The NDA, which we expect to file in the second quarter will be supported by clinical trial data on more than 1,000 patients and real-world evidence on more than 65,000 patients through our partnership with Osmind.

FDA also guided us to seek the broader indication of depression in patients who may have suicidality rather than simply seeking an approval for patients who have suicidality, which applies to more than 10 million Americans. In April, the regulatory environment evolved further. On April 18, President Trump signed an executive order titled Accelerating Medical Treatment for Serious Mental Illness, directing Acceleration of approval pathways for psychedelic medicines to treat depression, PTSD and suicidality and directing FDA to award Commission's National Priority vouchers to qualifying drugs. The presidential order specifically directs the use of real-world evidence in the approval process for this class of drugs.

Congressional appropriations language has similarly been filed, encouraging the use of real-world evidence in approval of drugs for suicidal depression and PTSD. We've applied for commission's national priority voucher in support of our NDA. For context, the current generic ketamine market exceeds $750 million per year, not counting the shadow market of ketamine that's being bought through compounding pharmacies, while SPRAVATO generates approximately $2 billion annually despite labeling that does not include reduction in suicidality. Moving to NRX-101. When we advance two parallel tracks in our original indication of suicidal bipolar depression, we've initiated an NDA filing with submission of Module 3 manufacturing files, and we're requesting rolling review under our Breakthrough Therapy Designation.

Separately, however, on May 7, we received FDA clearance to proceed with the MIND1 trial, a Phase IIb/III study of NRX-101 versus placebo as an adjunct to robotic-assisted TMS using an accelerated ONE-D protocol. The trial is designed to enroll 400 participants across a leading academic teaching hospital, HOPE therapeutics clinics and U.S. military treatment facilities with nondilutive federal funding anticipated. This use of NRX-101 was not anticipated until recent data have shown a doubling of clinical response and an eightfold increase in remission from depression when D-cycloserine is added to standard transcranial magnetic stimulation therapy. The market opportunity for this indication is in excess of $1 billion.

We've also achieved nonclinical validation of a proprietary extended-release form of D-cycloserine designed to support TMS augmentation. The MIND1 trial will be conducted by NRx Defense Systems, a Florida-based R&D subsidiary we incorporated in April. NRx Defense Systems is led by Dr. Dennis McBride, retired Navy Captain, a former DARPA program manager. He served two terms as the DARPA program manager and former senior executive, both in the National Defense University and in the Office of the Secretary of Defense. The robotic-enabled TMS prototype is being developed in combination with Zeta Surgical, whose AI-powered neuro navigation platform has already received FDA 510 clearance for TMS navigation.

We plan to unveil the prototype of Zeta at the Clinical TMS Society Annual Meeting in Boston in early June. Depression, if you want to see it, touch it, feel it first hand, please join us. Depression and PTSD carry a fivefold increased risk in frontline troops and first responders and personnel who are on standard antidepressants are not combat deployed a short-term nondisqualifying treatment is both a health care imperative and a force readiness priority, not only in the military setting, but in the setting of firefighters, police officers and other first responders. Turning to HOPE Therapeutics. We operated five Florida clinics during the quarter and expect 8 or more locations by the end of the second quarter.

In February, we appointed Professor Josh Brown of Harvard/McLean as Chief Medical Innovation Officer, joining Dr. Rebecca Cohen, our Medical Director. In March, HOPE announced a partnership with EMOBOT Health to deploy its AI-driven depression thermometer. That's a cell phone app that can actually measure your level of depression at a very high correlation with standard depression measures. EMOBOT passively analyzes facial expressions, vocal tones and actigraphy through a background smartphone application with clinical validation showing strong concordance against both MADRS and PHQ-9. This addresses a critical blind spot in the care of patients with depression suicidality.

Approximately 50% of patients with treatment-resistant depression relapse within 6 to 12 months, and that relapse is often undetected between visits As I've said, we expect every patient in our network to be on EMOBOT. We continue to integrate our partnership with neurocare AG, which brings together the combined clinic base together with an installed base of more than 400 Apollo TMS machines across the U.S. Finally, an important pipeline expansion occurred just in the past few weeks. We, just last week, formed Geneuro Inc., a Florida-based subsidiary built around a newly acquired portfolio targeting human endogenous retroviruses or HERVs, which are implicated in schizophrenia, multiple sclerosis, ALS, autism and optic neuritis.

The portfolio was acquired through a Swiss Court Supervised liquidation sale of Geneuro, SA, Swiss company funded with existing cash and includes a broad patent portfolio, cell lines, antibodies, regulatory files and data from pre-completed human clinical trials. Dr. Herve Perron, formerly Chief Scientist of Geneuro, SA, has joined as our Chief Scientist and Professor Marion Leboyer, who joined our advisory board several years ago, and whose intellectual property whose patents led us to this portfolio will lead the anti-HERV-W program in schizophrenia. We anticipate supporting Geneuro through non-dilutive investment channels. With that, I'll turn it over to Mike to review our financial results. Mr. Abrams.

Michael Abrams: Thank you, John. For the 3 months ended March 31, 2026, Rx Pharmaceuticals reported a net loss of approximately $1.4 million or $0.04 per share as compared to a net loss of approximately $5.5 million or $0.34 per share for the 3 months ended March 31, 2025, representing a 74% and year-over-year reduction. This change is primarily related to the impact of certain fair value accounting measures and other nonrecurring charges. For the 3 months ended March 31, 2026, NRx reported a loss from operations of $4.7 million versus a loss from operations of $3.8 million for the comparable quarter in 2025.

The change is primarily driven by certain costs related to certain -- several targeted strategic initiatives advanced during the quarter ended March 31, 2026, which management believes will drive significant short- and long-term value for shareholders, including, but not limited to, progress toward the approval of our first drug product, aligning resources for an anticipated near-term commercial launch, augmenting and expanding profitable clinic operations, enhancing our overall intellectual property portfolio and growing our development pipeline with new assets. For the 3 months ended March 31, 2026, research and development expense was approximately $1.3 million as compared to approximately $0.8 million for the 3 months ended March 31, 2025.

General and administrative expense, which includes selling costs for the 3 months ended March 31, 2026, was approximately $3.8 million as compared to approximately $2.9 million for the 3 months ended March 31, 2025. The drivers of the changes of both research and development and G&A expense were both primarily driven, as mentioned above, certain costs related to our execution towards several targeted strategic initiatives advanced during the quarter ended March 31, 2026. As of March 31, 2026, the company had approximately $6.7 million in cash and cash equivalents.

Management believes current cash resources, anticipated growth in clinic running, ongoing cost reduction initiatives and continued availability of the company's active at-the-market offering will be sufficient to support operations through at least 2026. Subsequent to quarter end, the company generated approximately $7 million in gross proceeds from its at-the-market facility through the sale of common stock. With that, I turn the call back over to Jon. Jonathan?

Jonathan Javitt: Thank you, Mike. We made meaningful progress on each of our programs in the first quarter. KETAFREE continues to advance through final FDA review. The NRX-100 NDA is on track for submission this quarter. the MIND1 trial has FDA clearance to proceed, and we expect nondilutive funding to support it in partnership with the military sites that plan to deploy the trial. HOPE Therapeutics continues to add clinical sites and generate revenue. Geneuro adds a new platform for serious neurological and autoimmune disease supported through nondilutive channels. Just to give you one example, the patent for treatment of endogenous retrovirus infection that is shown to be implicated in ALS is co-owned with the U.S.

National Institutes of Health and the prior company had a cooperative research and development agreement with the NIH. We're deeply grateful to our team, to our patients and their families to our shareholders for the trust they place in us, our goal of bringing hope to life is closer than ever. Operator, we're now ready to take questions.

Operator: [Operator Instructions] Your first question is from Tom Shrader from BTIG.

Thomas Shrader: A couple of operational ones for me. For KETAFREE, I understand there's need. What does the channel look like for distribution? How much do you have to build? Do you -- are the centers your customers? Or will this go through larger distributors. I'm just curious how much on the ground work is involved here? And then I have a real-world follow-up.

Jonathan Javitt: Well, you're describing -- thank you, Tom. And as always, you get right to the heart of the matter. You're describing two different channels. There's the existing hospital channel for ketamine, the reference drug is Ketalar and given the drug shortages and what we believe will be a perception of not only of quality but U.S. manufacturing and reliability. We belie that with standard locking and tackling for lack of a better word. And as you see the team that Glenn is bringing on to support that process. in terms of payer outreach in terms of major accounts at reach, part of our preservative-free ketamine strategy is that traditional market.

But the other part is the clinic market that right now really doesn't have access to the wholesalers. And we've tested this. We've had our clinics call and try to buy from wholesalers. And so far, not a single one of our clinics has succeeded in obtaining a single vial of ketamine from any of the traditional wholesalers. The wholesalers really are uninterested in the most rapidly growing area of the clinic space. So those clinics are required to rely on a web of compounding pharmacies. And we intend to displace that compounded product with reliably manufactured FDA-approved GMP product.

So it's a two-pronged strategy at a time when not only is the psychiatry clinic market for ketamine rapidly growing, -- but as opioids are increasingly restricted in their availability and their prescribability, there is an increasing reliance on ketamine to treat pain syndromes as well.

Thomas Shrader: Got it. Got it. Okay. And then on the real-world ketamine data, I understand you have 65,000 records. What is the level of understanding with the FDA as to what they really want to see in those records? And is that all negotiated? We have 65,000 records that show the boxes you want to see filled? Or is that a negotiation that's on going? I mean 65,000 is a lot. It's probably 60,000 more than you need if they like the record. So I'm just kind of curious where that process is in agreeing on what these records need to show?

Jonathan Javitt: And when we say records, we say record -- we mean records on 65,000 unique patients. At the risk of sounding numerous, everything with the FDA is a negotiation. But it's a negotiation that occurs through well-established channels. So what we agreed to in our meeting with FDA was we would -- they acknowledge that the preliminary cuts of the data looks promising. Osmind has previously published data on about 20,000 patients, and that was part of our meeting package. So what we agreed is that we would submit a statistical analysis plan just in the same way that one submits a statistical analysis plan for a proposed clinical trial.

So that before we spin the data, before we do the first analysis, we will have agreed with FDA on what statistical tests will be used, which patients will be included and excluded, how they'll be categorized so that when we do the analysis, we're not going to be in a position where we keep crunching the data over and over again, but sort of measured twice, cut once. So right now, we're waiting for FDA's response to our statistical analysis plan. And as soon as we've agreed on exactly what tests will be used, we'll apply that and submit the data.

Thomas Shrader: And any time marks for any of that, that you can share?

Jonathan Javitt: Well, there are some regulatory costs involved. So we're expecting FDA to come back to us approximately by the end of the month. I don't want to give you an exact date, but I don't have it at my fingertips, but that's about the time frame.

Operator: Your next question is from [ Omer Perez ] from [ Lucid Capital Market ]

Unknown Analyst: Jonathan, I was wondering if you could help us understand the shortage, the ketamine shortage. What are the bottlenecks there, whether it's raw material or the scale of manufacturing and how do you plan to overcome that shortage?

Jonathan Javitt: Well, we're not in a very good position to understand other people's products.

We know there is a shortage, whether it's a lack of glass vials, a lack of manufacturing capability for whatever reason that shortage exists, all we can really do is worry about our business and make sure we can address the shortage and do that by having a couple of years of ketamine drug ingredient in the warehouse by having high-volume assembly lines using blow-fill seal that are capable of making 1 million units in a single week if you run the line around the clock by having a manufacturing partner that literally has the loading dock capacity to get the raw materials in and the finished goods out the door.

So we know how to address the shortage, but I'm not sure I can tell you exactly why the supply chain is undersupplied.

Unknown Analyst: Yes. So raw material doesn't seem to be an issue?

Jonathan Javitt: It's not an issue for us. Availability of raw material is not a problem. I can't tell you the exact situation with pharmaceutical-grade glass today. I can tell you that during COVID, people were backed up a year. Pharmaceutical glass is kind of a problem worldwide.

Unknown Analyst: Yes. And somewhat related, if KETAFREE is approved, what do you anticipate the FDA's action would be towards a preservative-free ketamine as the solution across the industry?

Jonathan Javitt: Well, I would never want to predict what a regulatory agency will do. I can say that the current Secretary of Health has been quite vocal in his view of the need to remove toxic preservatives from -- certainly from foods and vaccines. He's certainly not been quiet about that throughout his career. The new acting commissioner of the FDA has been quite vocal about his view of safety and removal of toxic preservatives in various context. And the law says that all ingredients in a drug should be safe. This particular preservative was put into ketamine back in the 1970s. And in general, nobody has really looked at the formulation until we got involved.

Quite frankly, when we got involved, I asked, well, why is it there? And the answer was, oh, it's a necessary excipient, but ketamine will come out of solution without it. And I said really. And part of the reason that happened was I was involved back in the mid-1990s. We tried to figure out why does everybody with glaucoma have dry eye syndrome. And it turned out that it was the benzalkonium chloride in the eye drops that was killing the essential lipid component of human tears. So that's how I first learned about this class of preservatives. And that's why you see preservative-free eye drops on all the drug store shelves.

So it will be interesting to see how the regulatory world ultimately reacts to this. But I think in general, the regulatory environment is pro-safety and anti-preservative.

Unknown Analyst: Okay. And maybe one last question. Once you file the NRX-100 NDA, how soon do you anticipate to learn whether you got the priority review, the voucher?

Jonathan Javitt: Generally, that's a 6-month process. But remember, we already have Fast Track approved for NRX-100. So we're already entitled to priority review.

Operator: [Operator Instructions] And your next question is from Patrick Trucchio from H.C. Wainwright.

Patrick Trucchio: Just first on KETAFREE. I thought you mentioned that the commercial manufacturing is now initiated a $1 million per dose month level. I'm wondering what inventory level do you expect to have available at the time of the launch?

Jonathan Javitt: At the time of the launch, we'll have at least 1 million units in the warehouse. And depending on what we see between now and then, we may take that up by 0.5 million or 1 million units.

Patrick Trucchio: Got it. And for NRX-100, mentioned that have fast track review and that maybe hearing back on the CMPV could take 6 months. I guess, does this imply that you might be able to get a quicker review just with the standard Fast Track?

Jonathan Javitt: Well, I don't know if anybody knows exactly how much a CMPV speeds up the process, but priority review is a pretty well-established pathway, and we know it does speed up the process. So could CMPV further speed the process? Could CMPV further increase the likelihood of an approval? I think those are all questions that remain to be seen. I think the most important thing is to come to agreement with FDA on the real-world evidence and get that submitted.

And in that regard, the President's executive order from April is enormously supportive and completely apart from the executive order from the White House, if you look at the appropriations language in the FDA budget appropriation for this year, Congress has focused on the use of real-world evidence in the approval of drugs for depression and suicidality. So I think there's an increasing recognition that this is just something that's needed for the health of the American people and it ought to get the most serious possible and expeditious possible review.

Patrick Trucchio: Yes. That makes sense. And then just lastly, on the MIND1 trial for NRX-101 plus TMS. I'm wondering if you could talk a little bit more about this trial and including whether you would expect it to be registration-enabling if positive.

Jonathan Javitt: Well, it's certainly a large enough sample that if one had a dramatically positive result, and that wouldn't be P0.05, but P0.01 or better. given the priority that currently exists around treating depression and suicidality, again, back to the President's executive order, back to many things the Secretary said, back to things Congress is saying, a dramatic effect in this trial on par with previous results that have been seen where D-cycloserine doubled the effect of transcranial magnetic stimulation on depression, but increased that effect more than eightfold with respect to reducing suicidality.

I think if we saw something that was as dramatic as that, the possibility of seeking an approval based on one trial would be a very real possibility. But until the data is in hand, I'm not sure that our speculation matters. What matters is are getting this trial fielded in partnership with our military colleagues, with our academic colleagues. And if you take a look at the success that Professor Brown has had in this area over the last couple of years, we're extraordinarily excited to have him as the principal investigator for this work.

Operator: There are no further questions at this time. I will now hand the call back over to Jonathan Javitt for the closing remarks.

Jonathan Javitt: Well, thank you. As I hope you can tell, this has been a quarter of heads down work. Our team has grown. Our proximity to market, we believe, has substantially increased or got shorter to be precise. And we're incredibly grateful to the investors who've come on board, who have lent their support and given us their confidence. So thank you very much, and we look forward to seeing you soon.

Operator: Thank you. Ladies and gentlemen, the conference has now ended. Thank you all for joining. You may now disconnect your lines.